Repligen Corporation (NASDAQ: RGEN) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $10.4B. The Maz Rating grades it against the other companies in its sector.
Repligen Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $162.18, Repligen Corporation trades at 12.8x sales and 4.4x book value, with an EV/EBITDA of 82.1. Over the last twelve months it generated about $808M of revenue and a net loss of $13M. It runs a gross margin of 51.1%, an operating margin of 2.3% and a net margin of -1.5%. It shows return on equity of -0.6%, return on invested capital of -1.0% and a free cash flow yield of 1.0%. On the balance sheet: a debt-to-equity ratio of 0.33 and a current ratio of 9.88. Over the past 52 weeks the share price ranged from $100.99 to $198.87, with a beta of 1.12.
Repligen Corporation does not currently pay a dividend.
24 Wall Street analyst ratings cover the stock: 1 Strong Buy, 21 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Repligen Corporation (RGEN) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 5.58% / 30% · (Cash+Inv) / Mkt Cap (36m) 8.66% / 30% · Interest income / Revenue 3.34% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 5.58% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 8.66% / 33% · Receivables / Mkt Cap (36m) 1.52% / 49% · Interest income / Revenue 3.34% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 5.58% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 8.66% / 33.33% · Receivables / Mkt Cap (24m) 1.52% / 33.33% · Interest income / Revenue 3.34% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 19.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 27.4% / 33.33% · Receivables / Avg Assets (4Q) 5.27% / 33.33% · Interest income / Revenue 3.34% / 5% | Pass |
| FTSE | Debt / Total Assets 19.0% / 33.33% · (Cash+ST Inv) / Total Assets 29.5% / 33.33% · (Cash+Recv) / Total Assets 34.7% / 33.33% · Interest income / Revenue 3.34% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Repligen Corporation (RGEN) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. Repligen Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 3.34% of each dividend: Repligen Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.